Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

Published:2024-08-30 Issue: Volume: Page:
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Mori Nami,Tamaki Nobuharu,Takaki Shintaro,Tsuji Keiji,Tada Toshifumi,Nakamura Shinichiro,Ochi Hironori,Mashiba Toshie,Doisaki Masao,Marusawa Hiroyuki,Kobashi Haruhiko,Fujii Hideki,Ogawa Chikara,Nonogi Michiko,Arai Hirotaka,Uchida Yasushi,Urawa Naohito,Narita Ryoichi,Akahane Takehiro,Kondo Masahiko,Yasui Yutaka,Tsuchiya Kaoru,Izumi Namiki,Kurosaki Masayuki

Funder

Japan Agency for Medical Research and Development

Ministry of Health, Labour and Welfare

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10637-024-01470-y.pdf

Reference24 articles.

1. Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263

2. Tan DJH, Ng CH, Muthiah M et al (2024) Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism 152:155744

3. Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223–238

4. Kirino S, Tamaki N, Kurosaki M et al (2023) Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 53:35–42

5. Tamaki N, Kurosaki M, Yasui Y et al (2021) Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. Clin Infect Dis 73:e3349–e3354